High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia

Blood Reviews

Volumn 11, Issue 1, 1997, Pages 39-45

  Cole, N ^a   Gibson, B E ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTILEUKEMIC AGENT; ASPARAGINASE; CYTARABINE; FLUDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; DRUG EFFICACY; DRUG POTENTIATION; EYE TOXICITY; LIVER TOXICITY; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; RASH; VOMITING;

EID: 0030925254     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(97)90005-9     Document Type: Article

References (27)

1. De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology 4th edn, vol 2. Philadelphia, PA: JB Lippincott, 1993.
2. Hedley DW, McCulloch EA. Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukaemia with cytosine arabinoside: role of bcl-2. Leukaemia 1996; 10: 1143-1149.
3. Capizzi RL, White C. The pharmacologic basis for the efficacy of high dose Ara-C and sequential asparaginase in adult acute myelogenous leukaemia. Yale J Biol Med 1988; 61: 11-22.
4. Capizzi RL, Poole H, Cooper HR et al. Treatment of poor risk acute leukaemia with sequential high dose ara C and asparaginase. Blood 1984; 63: 694-700.
5. Gjrniayer ER, Schrudrieser W, Panzer S. Toxicity of sequential high dose ara C asparaginase treatment in childhood poor risk leukaemia. Blut 1986; 53: 309-314.
6. Capizzi RL, Powell BL. Sequential high-dose ara C and asparaginase versus high-dose ara C alone in the treatment of patients with relapsed and refractory acute leukaemias. Sem Oncol 1987; 114(2) (Suppl 1): 40-50.
7. Visani G, Tosi P, Zinzani PL et al. FLAG (fludarabine + high dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukaemias. Leukemia 1994; 8: 1842-1846.
8. Estey E, Thall P, Ardeeff M et al. Use of granulocyte colony stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukaemia or myelodysplastic syndromes. Comparison with fludarabine plus cytrabine without granulocyte colony stimulating factor. J Clin Oncol 1994; 12: 671-678.
9. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukaemia during therapy. J Clin Oncol 1993; 11: 116-124.
10. Keating M, Kantarjian H, O'Brien S et al. FLAG-IDA, an effective regimen for high risk AML. Ann Hematol 1997; 74 (Suppl 1): A7 (Abstract).
11. Buchner T, Hiddemann W, Wormann B et al. Intensified therapy of AML: the role of the HAM combination. Ann Hematol 1997; 74 (Suppl 1): A5.
12. Bishop JF, Matthews JP, Young Graham A. A randomised study of high dose cytarabine in induction in acute myeloid leukaemia. Blood 1996; 87: 1710-1717.
13. Phillips GL, Reece DE, Shepherd JD et al. High dose cytarabine induction and post remission chemotherapy for the treatment of acute myelogenous leukaemia in adults. Blood 1991; 77: 1429-1435.
14. Schiller G, Gajewski J, Territo M et al. Long term outcome of high dose cytarabine based consolidation chemotherapy for adults with acute myelogenous leukaemia. Blood 1992; 80: 2977-2982.
15. Cassileth PA, Lynch E, Hines JD et al. Varying intensity of post remission therapy in acute myeloid leukaemias. Blood 1992; 79: 1924-1930.
16. Mayer RJ, Davis RB, Schiffer CA et al. Intensive post remission chemotherapy in adults with acute myeloid leukaemia. N Engl J Med 1994; 331: 896-903.
17. Ferrant A, Doyen C, Delannoy A et al. High dose cytosine arabinoside intensification for acute nonlymphocytic leukaemia in patients over 56 years of age. Ann Hematol 1992; 64: 185-189.
18. Rowe J M, Liesveld J L. Treatment and prognostic factors in acute myeloid leukaemia. Baillière's Clin Haematol 1996; 9: 87-101.
19. Lowenberg B. Post remission treatment of acute myelogenous leukemia. (Editorial). N Engl J Med 1995; 332: 260-262.
20. Ravindranath Y, Yeager AM, Chang MN et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukaemia in childhood. N Engl J Med 1996; 334: 1428-1434.
21. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukaemia. N Engl J Med 1995; 332: 217-223.
22. Burnett AK, Goldstone AH, Stevens RF et al. The role of BMT in addition to intensive chemotherapy in AML in first CR: results of the MRC AML-10 trial. Blood 1994; 84 (Suppl 1): 252A (Abstract).
23. Hiddemann W, Fonatsch C, Wormann B et al. Cytogenetic subgroups of AML and outcome from high dose versus conventional dose ara-c as part of double induction. Blood 1995; 86 (Suppl. 1): 267a.
24. Grever MR. Treatment of patients with acute non lymphocytic leukaemia not in remission. Sem Oncol 1987; 14: 416-424.
25. Rees JKH. Aspects of treatment of acute myeloid leukaemia in adults. Curr Opin Oncol 1993; 5: 53-70.
26. Herzig RH, Wolff SN, Lazarus HM et al. High dose cytosine arabinoside in the treatment for refractory leukaemia. Blood 1983; 62: 361-369.
27. Baker JW, Royer GL, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991; 9: 679-693.